STAT+: Pharmalittle: We’re reading about a Lilly weight loss trial, TrumpRx shortcomings, and more

Story Timeline

1. 2026-02-23
   STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more (Stat News)
2. 2026-02-24
   STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more (Stat News)
3. 2026-02-25
   STAT+: Pharmalittle: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more (Stat News)+1 more source
4. 2026-02-26
   STAT+: Rare disease advocates fume over FDA’s mixed signals (Stat News)+1 more source
5. 2026-03-02
   STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more (Stat News)
6. 2026-03-04
   STAT+: Pharmalittle: We’re reading about Moderna’s $2.25 billion settlement, FDA warning letters, and more (Stat News)+1 more source
7. 2026-03-09
   STAT+: As controversial decisions mount, FDA shuns public advisory meetings (Stat News)+1 more source
8. 2026-03-10
   STAT+: BioNTech founders to depart, form new mRNA-focused company (Stat News)+1 more source

Score BreakdownRisk 70

Stories gain Lindy status through source reputation, network consensus, and time survival.